Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies
- 10 March 2009
- Vol. 27 (11) , 1764-1770
- https://doi.org/10.1016/j.vaccine.2009.01.018
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation AntigensJournal of Clinical Oncology, 2008
- Preventing the Spontaneous Modification of an HLA-A2-Restricted Peptide at an N-Terminal Glutamine or an Internal Cysteine Residue Enhances Peptide AntigenicityJournal of Immunotherapy, 2004
- Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic CellsJournal of Clinical Oncology, 2003
- Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.2003
- Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.2001
- Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patientsInternational Journal of Cancer, 2001
- Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV MelanomaThe Journal of Experimental Medicine, 1999
- Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.1999
- Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanomaNature Medicine, 1998
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998